Patients enrolled into Phase III diabetic retinopathy drug trial

Article

Vitreoretinal Technologies, Inc has begun to enrol and treat diabetic retinopathy patients in the clinical trial for its pharmaceutical treatment Vitreosolve.

Vitreoretinal Technologies, Inc has begun to enrol and treat diabetic retinopathy patients in the clinical trial for its pharmaceutical treatment Vitreosolve.

Vitreosolve, a small molecule currently used for vitreous liquefaction as an adjunct to pars plana vitrectomy surgery, is now being evaluated as a preventative treatment for diabetic retinopathy. There are currently no approved pharmaceutical treatments indicated for this condition.

The multinational Phase III trial, investigating safety and efficacy, is the first of two studies required for a New Drug Application (NDA) to be granted by the FDA. Patients are currently being enrolled and treated in India and the US.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.